Abstract
Get full access to this article
View all access options for this article.
References
1.WRAL TechWire . Pfizer adding 300 jobs, investing $500M at Sanford campus . 2019 . Available at: https://www.wraltechwire.com/2019/08/21/pfizer-to-announce-big-boost-in-jobs-investment-at-sanford-campus/ (last accessed August 22 , 2019
2.Pfizer . Pfizer invests half billion dollars to Advance State-of-the-Art Gene Therapy Facility in Sanford, North Carolina . 2019 . Available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_invests_half_billion_dollars_to_advance_state_of_the_art_gene_therapy_facility_in_sanford_north_carolina (last accessed August 22 , 2019
3.
Winters
P.
Novartis CEO Says FDA Process Could Have Been Handled Better . Bloomberg News , August 17. 2019 . https://www.bloomberg.com/news/articles/2019-08-17/novartis-ceo-says-fda-process-could-have-been-handled-better (last accessed August 19 , 2019
4.Novartis . Novartis stands behind Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy . 2019 . https://www.novartis.com/news/media-releases/novartis-stands-behind-zolgensma-onasemnogene-abeparvovec-xioi-treatment-children-less-2-years-age-spinal-muscular-atrophy (last accessed August 19 , 2019
5.U.S. Food and Drug Administration . Statement on data accuracy issues with recently approved gene therapy . 2019 . https://www.fda.gov/news-events/press-announcements/statement-data-accuracy-issues-recently-approved-gene-therapy (last accessed August 19 , 2019
6.AveXis, a Novartis Company . AveXis statement on changes to senior leadership team . 2019 . https://avexis.gcs-web.com/news-releases/news-release-details/avexis-statement-changes-senior-leadership-team (last accessed August 19 , 2019
7.
Liu
A
. Ousted AveXis CSO denies wrongdoing in Novartis data scandal, taps Elon Musk lawyer . FiercePharma August 20. 2019 . https://www.fiercepharma.com/pharma/ousted-avexis-cso-denies-wrongdoing-zolgensma-data-scandal-taps-elon-musk-lawyer (last accessed August 20 , 2019
8.Pfizer and Sangamo Therapeutics . Sangamo and Pfizer announce updated phase 1/2 results for SB-525 investigational hemophilia a gene therapy showing sustained increased factor VIII levels . 2019 . https://investor.sangamo.com/news-releases/news-release-details/sangamo-and-pfizer-announce-updated-phase-12-results-sb-525 (last accessed August 18 , 2019
9.Amicus Therapeutics . Amicus announces positive interim clinical data for AAV gene therapy in children with CLN6 batten disease . 2019 . http://ir.amicusrx.com/news-releases/news-release-details/amicus-announces-positive-interim-clinical-data-aav-gene-therapy (last accessed August 18 , 2019
10.Allergan and Editas Medicine . Allergan and Editas medicine initiate the brilliance phase 1/2 clinical trial of AGN-151587 (EDIT-101) for the treatment of LCA10 . 2019 . http://ir.editasmedicine.com/news-releases/news-release-details/allergan-and-editas-medicine-initiate-brilliance-phase-12 (last accessed August 19 , 2019
11.Allergan and Editas Medicine . Single ascending dose study in participants with LCA10 . ClinicalTrials.gov. Last updated July 23. 2019 . https://clinicaltrials.gov/ct2/show/NCT03872479 (last accessed August 20 , 2019
12.uniQure . uniQure announces 36 weeks of follow-up data from phase IIb study of AMT-061 and long-term follow-up data for AMT-060 in patients with hemophilia B . 2019 . https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=3624692&lang=en-GB&companycode=nl-qure&v=(last accessed August 19 , 2019